CTLA4 and autoimmune disease: Since treatment of cancer patients with checkpoint-inhibitors (anti-CTLA4) has led to autoimmune diseases as serious adverse events [43–46], we next treated healthy female WT mice with CTLA4-AB, starting at age 11 weeks (Fig. 2e).